• Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting and patient treatment ongoing
• Data update expected in 2027, with trial completion in 2028
• Trial-in-progress poster to be presented at ESMO 2026 in October

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.